TTo evaluate safety and performance of the Evermine 50-50μm Everolimus-Eluting Coronary Stent System (EES) in the treatment of patients with new native coronary artery lesions.
Phase 4
Completed
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Registration Number
- CTRI/2017/09/009939
- Lead Sponsor
- Meril Life Sciences Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 171
Inclusion Criteria
1. All patients who have been treated with Evermine 50 EES.
2. Patients who are contactable, willing to participate will be taken into the study by either signing voluntary informed consent form or by taking telephonic consent of patient.
Exclusion Criteria
1. There are no exclusion criteria for this study.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method